United States Patent 8,022,279 Daunorubicin-Cytarabine Liposome (DNR:AraC 1:5) Scope and Claim Landscape
US Drug Patent 8,022,279 claims a specific parenteral liposomal co-delivery of daunorubicin (DNR) and cytarabine (AraC) with a defined drug mole ratio and a defined pharmacokinetic maintenance window in blood, plus narrowing limitations on co-encapsulation, liposome size (nm), lipid composition, and combination therapy scope (no additional therapeutics). The patent’s core risk for generic or biosimilar-like entry is that it can be avoided only by changing at least one of: (i) DNR:AraC mole ratio, (ii) whether ratio is maintained in blood for the claimed duration, (iii) co-encapsulation state, (iv) liposome mean diameter target, or (v) lipid composition, depending on which claim is asserted.
The landscape around US 8,022,279 is best analyzed by claim buckets: composition of liposomal co-associated DNR/AraC (ratio + PK maintenance), manufacturing/structure (co-encapsulation; size; lipid recipe), and method-of-use (leukemia treatment; human; ALL/AML). That separation drives both design-around and litigation posture.
What is the scope of US Patent 8,022,279 claims covering liposomal daunorubicin and cytarabine at a 1:5 mole ratio?
Claim 1 is the independent anchor. It defines the protected invention at a functional PK level and a compositional level.
Claim 1 core limitations (composition; parenteral; liposomes; ratio + blood maintenance)
Claim 1 requires all of the following:
- Parenteral composition to a subject.
- Liposomes have DNR and AraC associated with the liposomes.
- Mole ratio of DNR:AraC about 1:5.
- The DNR and AraC are associated with liposomes so that the mole ratio is maintained in the blood for at least one hour after administration.
Practical scope:
- “Associated with liposomes” is broader than “encapsulated.” It can cover DNR/AraC inside the aqueous core, in the bilayer, or surface-associated, as long as the blood DNR:AraC mole ratio remains in that target relationship for the stated minimum time.
- The “maintained in the blood for at least one hour” element is a performance/PK functional requirement, which becomes central in infringement through measurement evidence (sampling schedules and assay methods).
Claim 2 (co-encapsulation)
Claim 2 narrows Claim 1 by requiring co-encapsulation (DNR and AraC both encapsulated within the same liposomal structure). This is a meaningful design-around lever if a competitor uses:
- separate liposome populations (DNR-only and AraC-only), or
- one drug surface-associated and one encapsulated, or
- different assembly methods where co-encapsulation fails.
Claim 3 and 4 (liposome size envelope)
- Claim 3: mean diameter 4.5 to 500 nm.
- Claim 4: mean diameter < 250 nm.
Scope impact: size claims are often easier to adjust than PK ratio maintenance. If infringement hinges on Claim 1, size limits are not required. If asserted via Claim 3/4 (or for fallback positions), size becomes a clear lever.
Claim 5 and 6 (lipid recipe)
- Claim 5: liposomes comprise phosphatidylcholine-containing lipid and/or charged lipid and/or sterol.
- Claim 6: specific lipid molar ratio: DSPC:DSPG:cholesterol ~ 7:2:1.
Claim 5 provides a broad lipid class framing; Claim 6 provides a narrow embodiment-like anchor. A generic entrant trying to avoid Claim 6 specifically can still practice within Claim 5 unless the asserted claim is specifically Claim 6.
What is the scope of US Patent 8,022,279 method-of-use claims for leukemia?
Claims 7 to 10 are method claims that depend on Claim 1’s composition.
Claim 7 and 8 (treatment; subject categories)
- Claim 7: method to treat leukemia by administering an effective amount of the Claim 1 composition.
- Claim 8: subject is human.
Claim 9 (non-human mammal or avian)
Claim 9 broadens target subjects beyond human.
Claim 10 (ALL or AML)
Claim 10 narrows leukemia type to ALL or AML.
Scope impact:
Method-of-use is typically enforceable only where the accused product is used as claimed and where the clinical protocol matches “effective amount” and the indicated leukemia types. If a competitor sells a liposomal DNR/AraC product but its labeling or clinical use avoids ALL/AML, method-use enforcement risk can change.
What formulations are protected by US 8,022,279 including co-encapsulation, blood ratio maintenance >4 hours, and “no additional therapeutics”?
US 8,022,279 contains a second composition bundle in Claims 11 through 14 that is tighter than Claim 1.
Claim 11 (no additional therapeutic agents)
Claim 11 requires the composition comprises no therapeutic agents additional to DNR and AraC.
This is a strong scope limiter because it bars three-drug regimens and many combination-loaded liposomes (even where DNR:AraC ratio is maintained).
Claim 12 (blood ratio maintenance at least four hours)
Claim 12 requires:
- co-encapsulation, and
- DNR:AraC mole ratio maintained in blood for at least four hours.
This moves the functional PK window from Claim 1’s “at least one hour” to “at least four hours,” substantially narrowing protected performance.
Claim 13 (integrated narrow package claim)
Claim 13 aggregates multiple restrictions into one composition claim:
- DNR:AraC mole ratio about 1:5
- co-encapsulated
- ratio maintained in blood at least four hours
- mean diameter < 250 nm
- no additional therapeutic agents beyond DNR and AraC
Claim 14 (specific lipid molar ratio DSPC:DSPG:cholesterol ~7:2:1)
Claim 14 narrows Claim 13 to the specific lipid recipe (DSPC:DSPG:cholesterol 7:2:1).
Scope impact:
Claims 13/14 are the “most infringement-targetable” if an accused product resembles a single embodiment-like DNR/AraC co-loaded small liposome with sustained co-exposure. They are also the easiest to design around systematically: alter liposome size, alter PK maintenance, break co-encapsulation, add other actives, or change lipid composition.
Which elements in US 8,022,279 are infringement-critical and which are easiest to design around?
Infringement-critical elements (highest evidentiary weight)
- DNR:AraC mole ratio ~1:5
- Often requires assay-based quantification of drug amounts in circulation or in the liposomal formulation prior to administration.
- “Ratio maintained in blood” for at least one hour or four hours
- Requires pharmacokinetic sampling and ratio calculations.
- Co-encapsulation vs broader “associated with liposomes”
- Co-encapsulation is structurally testable, while “associated” can be broader and harder to avoid.
- Mean diameter thresholds
- Particle sizing (e.g., DLS or NTA) controls Claim 3/4 and Claim 13.
Easier design-around levers (most actionable)
- Drop co-encapsulation (use separate liposomes or partial surface association) so Claim 2/12/13 fail.
- Shift ratio away from ~1:5 (manufacturing control plus measured blood ratios).
- Fail the PK maintenance duration (reduce stability or release kinetics so the ratio diverges before the “at least one hour” or “at least four hours” thresholds).
- Change mean diameter above 250 nm (for Claim 4 and Claim 13) while staying within Claim 3’s broader 4.5–500 nm range where relevant.
- Add another therapeutic agent to the same liposome formulation or regimen such that Claim 11/13 no-additional-therapeutics is not met.
- Change lipid recipe to avoid Claim 6/14 specifically (though Claim 5 remains broad).
How does the claim structure drive enforceability against generic or competitor liposomal DNR/AraC products?
Claim layering strategy
- Broadest independent claim: Claim 1 (association; 1:5; ratio maintained ≥1 hour).
- First narrowing: co-encapsulation (Claim 2).
- Particle sizing fallback: 4.5–500 nm (Claim 3), then <250 nm (Claim 4).
- Composition fallback: lipid classes (Claim 5) then specific molar recipe DSPC:DSPG:cholesterol 7:2:1 (Claim 6).
- Second independent-like narrowed package: Claims 13/14 (co-encapsulation + sustained ≥4 hours + <250 nm + no additional therapeutics + specific lipid recipe).
Litigation implication: Even if a challenger designs around the narrowest package (Claim 13/14), they may still face risk under Claim 1 if their formulation still achieves DNR:AraC association and maintains the blood mole ratio for ≥1 hour.
What does the patent’s functional “blood ratio maintained” requirement mean for testing in infringement?
US 8,022,279 uses a functional PK criterion rather than solely structural criteria.
What must be shown in an infringement analysis
- Define “mole ratio maintained in the blood” operationally:
- blood sampling timepoints after administration
- calculation of circulating (or measurable) DNR and AraC amounts
- determination that the DNR:AraC ratio remains within the “about 1:5” relationship for the required duration (≥1 hour for Claim 1; ≥4 hours for Claim 12/13)
What matters most for design-around
- Products that release DNR and AraC at different rates that cause ratio drift inside the first hour (for Claim 1) or inside the first four hours (for Claim 12/13) can fall outside the functional limitation even if the initial formulation ratio is set to 1:5.
How strong is the patent estate position based on claim breadth and narrowing?
Within the four-corner claim set you provided, US 8,022,279 is structurally strong for a specific technology pattern:
- It covers liposomal DNR/AraC delivery at a defined mole ratio and measured co-exposure duration.
- It uses multiple fallback narrows that can capture different competitor variants:
- co-encapsulation
- size windows
- lipid recipe
- no additional therapeutics
- method-of-use for leukemia
However, the enforcement strength depends heavily on whether an accused product meets the functional PK criterion. That shifts leverage to the evidentiary record for ratio-in-blood at the claimed timepoints.
Key claim map for US Patent 8,022,279 (what each claim adds)
| Claim |
Scope type |
Additional limitations beyond Claim 1 |
Direct “avoid by…” levers |
| 1 |
Composition; broad |
DNR:AraC ~1:5; associated with liposomes; ratio maintained in blood ≥1 hour |
change ratio, break ratio maintenance ≥1 hour, use different association profile |
| 2 |
Composition |
co-encapsulated |
use non-co-encapsulated architecture |
| 3 |
Composition |
mean diameter 4.5–500 nm |
shift size below 4.5 or above 500 if relevant |
| 4 |
Composition |
mean diameter <250 nm |
increase mean size to ≥250 |
| 5 |
Composition |
phosphatidylcholine-containing lipid and/or charged lipid and/or sterol |
change lipid class composition if asserted via Claim 5/depends |
| 6 |
Composition |
DSPC:DSPG:cholesterol ~7:2:1 |
change lipid molar recipe |
| 7 |
Method |
leukemia treatment; administer Claim 1 composition |
change composition elements so Claim 1 fails |
| 8 |
Method |
human subject |
avoid human use/labeling (limits enforcement posture) |
| 9 |
Method |
non-human mammal/avian |
avoid those uses |
| 10 |
Method |
leukemia is ALL or AML |
avoid/allay indicated use |
| 11 |
Composition |
no additional therapeutics beyond DNR/AraC |
add other therapeutics to formulation/regimen |
| 12 |
Composition |
co-encapsulated; ratio maintained ≥4 hours |
fail ≥4 hour maintenance |
| 13 |
Composition |
co-encapsulated; ≥4 hours maintenance; <250 nm; no additional therapeutics |
change any of: co-encapsulation, PK window, size, combination scope |
| 14 |
Composition |
DSPC:DSPG:cholesterol ~7:2:1 |
change lipid recipe |
What commercial risk does this create for liposomal DNR/AraC products targeting ALL/AML?
The business risk centers on three categories of competitive entry:
- Close-in reformulations that keep the same DNR:AraC 1:5 co-loading and sustained co-exposure window.
- Small-particle co-loaded liposomes (<250 nm) with co-encapsulation and no additional actives.
- Same-leukemia use patterns (ALL/AML) where method-of-use enforcement can be pursued if an accused composition matches Claim 1.
The most direct attack surface is for products that are essentially “same mechanism, same ratio, same sustained blood behavior.”
Key Takeaways
- US 8,022,279 protects a parenteral liposomal co-delivery of daunorubicin and cytarabine with a ~1:5 mole ratio and a functional requirement that the blood mole ratio is maintained for ≥1 hour (Claim 1) or ≥4 hours (Claims 12/13).
- Structural narrowing tracks: co-encapsulation (Claims 2/12/13) and particle size (<250 nm for Claims 4/13; 4.5–500 nm for Claim 3).
- Formulation narrowing tracks: no additional therapeutic agents (Claim 11/13) and a specific lipid composition DSPC:DSPG:cholesterol ~7:2:1 (Claims 6 and 14).
- Method claims cover leukemia treatment, including human and ALL/AML (Claims 7-10), but they depend on administering the protected composition.
FAQs
1) What is the main “design-around” strategy for US 8,022,279 infringement?
Fail at least one essential limitation: move the DNR:AraC ratio away from ~1:5, prevent the blood ratio from being maintained for the claimed duration (≥1 hour or ≥4 hours), avoid co-encapsulation where required, shift mean particle size above 250 nm for the narrower claims, or change lipid recipe and/or formulation combination scope.
2) Does US 8,022,279 require both drugs to be co-encapsulated in Claim 1?
No. Claim 1 requires DNR and AraC to be “associated with” liposomes. Co-encapsulation is a narrowing limitation in dependent Claims 2, 12, and 13.
3) How does the particle size limitation affect infringement risk?
Particle size is not required for Claim 1. It is required for Claims 3/4 and for Claim 13. If a competitor avoids those dependent claims, they still may face Claim 1 exposure if the ratio maintenance and association requirements are met.
4) Can a product with added therapeutics avoid Claims 11/13?
Yes, because Claim 11 and Claim 13 require the composition comprises no therapeutic agents additional to DNR and AraC. Adding another active in the composition can defeat those dependent claims.
5) What is the practical evidentiary battleground for the “ratio maintained in blood” element?
Blood sampling timepoints after dosing and assay-based quantification of circulating DNR and AraC followed by calculation of the DNR:AraC mole ratio stability through the required window (≥1 hour for Claim 1; ≥4 hours for Claims 12/13).
References
- United States Patent No. 8,022,279.
